Regeneron signs up to $125 million deal with Parabilis to target difficult drug targets

Regeneron announced a deal with Parabilis Medicines valued up to $2.2 billion, with an upfront payment of $125 million.

The agreement aims to give Regeneron access to Parabilis’s platform that discovers and validates hard-to-target disease proteins.

The move comes as Regeneron’s cancer pipeline has faced recent trial failures, prompting the company to explore new therapeutic avenues.

Under the deal, Parabilis will receive funding and collaborate with Regeneron on research, with potential milestones tied to successful target validation.